Limits...
The durability of sitagliptin in elderly patients with type 2 diabetes.

Hsieh CJ, Shen FC - Clin Interv Aging (2014)

Bottom Line: No changes in fasting plasma glucose, Cr, serum total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, body mass index, and microvascular complications were apparent.Sitagliptin has a durable effect and stabilizes microvascular complication progression in elderly patients.This study can provide useful data for clinicians and health care professionals using sitagliptin monotherapy in the treatment of elderly patients with T2DM.

View Article: PubMed Central - PubMed

Affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

ABSTRACT

Aim: To evaluate the durability of sitagliptin and to assess changes in clinical chronic complications following sitagliptin monotherapy for 48 months in elderly patients with type 2 diabetes mellitus (T2DM).

Subjects and methods: We enrolled 76 drug-naïve patients (40 women and 36 men; mean age: 71.3±11.7 years) with T2DM who received 25-100 mg of sitagliptin therapy from an outpatient clinic. The observational period for each patient was >48 months, beginning at the time sitagliptin therapy was initiated. The following were measured or performed at the beginning of each year: body mass index; serum total cholesterol, low-density lipoprotein, high-density lipoprotein; triglyceride levels; creatinine (Cr) levels; urine albumin and urine Cr; nonmydriatic fundusgraphy; and semiquantified neuropathy. The fasting plasma glucose and glycated hemoglobin (HbA1c) was measured every 3-6 months.

Results: The change in HbA1c was significantly reduced after 6 months of therapy (7.1%±0.8% to 6.3%±0.2%). No changes in fasting plasma glucose, Cr, serum total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, body mass index, and microvascular complications were apparent. Using repeated measures to test the sequential changes in HbA1c from month 6 to month 48, the test of within-subjects effect was not significant (P=0.34).

Conclusion: Sitagliptin has a durable effect and stabilizes microvascular complication progression in elderly patients. This study can provide useful data for clinicians and health care professionals using sitagliptin monotherapy in the treatment of elderly patients with T2DM.

Show MeSH

Related in: MedlinePlus

Change in HbA1c levels as a function of sitagliptin dose.Notes: The patients who received different doses of sitagliptin had apparent reductions in HbA1c from baseline during the first 6 months of treatment. The HbA1c levels remained stable in patients receiving different doses of sitagliptin between month 6 and month 48.Abbreviation: HbA1c, glycated hemoglobin.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4232051&req=5

f2-cia-9-1905: Change in HbA1c levels as a function of sitagliptin dose.Notes: The patients who received different doses of sitagliptin had apparent reductions in HbA1c from baseline during the first 6 months of treatment. The HbA1c levels remained stable in patients receiving different doses of sitagliptin between month 6 and month 48.Abbreviation: HbA1c, glycated hemoglobin.

Mentions: The patients who received different doses of sitagliptin had apparent reductions in HbA1c from baseline during the first 6 months of treatment (25 mg, 7.3%±1.3% and 6.0%±0.8%, respectively; 50 mg, 7.1%±0.8% and 6.3%±0.6%, respectively; and 100 mg, 7.1%±0.8% and 6.3%±0.6%, respectively; all P<0.001); the HbA1c levels remained stable in patients receiving different doses of sitagliptin between month 6 and month 48 (Figure 2). There were no statistically significant differences in HbA1c concentrations between sitagliptin regimens (P=0.23 [tests of the between-subjects effect]).


The durability of sitagliptin in elderly patients with type 2 diabetes.

Hsieh CJ, Shen FC - Clin Interv Aging (2014)

Change in HbA1c levels as a function of sitagliptin dose.Notes: The patients who received different doses of sitagliptin had apparent reductions in HbA1c from baseline during the first 6 months of treatment. The HbA1c levels remained stable in patients receiving different doses of sitagliptin between month 6 and month 48.Abbreviation: HbA1c, glycated hemoglobin.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4232051&req=5

f2-cia-9-1905: Change in HbA1c levels as a function of sitagliptin dose.Notes: The patients who received different doses of sitagliptin had apparent reductions in HbA1c from baseline during the first 6 months of treatment. The HbA1c levels remained stable in patients receiving different doses of sitagliptin between month 6 and month 48.Abbreviation: HbA1c, glycated hemoglobin.
Mentions: The patients who received different doses of sitagliptin had apparent reductions in HbA1c from baseline during the first 6 months of treatment (25 mg, 7.3%±1.3% and 6.0%±0.8%, respectively; 50 mg, 7.1%±0.8% and 6.3%±0.6%, respectively; and 100 mg, 7.1%±0.8% and 6.3%±0.6%, respectively; all P<0.001); the HbA1c levels remained stable in patients receiving different doses of sitagliptin between month 6 and month 48 (Figure 2). There were no statistically significant differences in HbA1c concentrations between sitagliptin regimens (P=0.23 [tests of the between-subjects effect]).

Bottom Line: No changes in fasting plasma glucose, Cr, serum total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, body mass index, and microvascular complications were apparent.Sitagliptin has a durable effect and stabilizes microvascular complication progression in elderly patients.This study can provide useful data for clinicians and health care professionals using sitagliptin monotherapy in the treatment of elderly patients with T2DM.

View Article: PubMed Central - PubMed

Affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

ABSTRACT

Aim: To evaluate the durability of sitagliptin and to assess changes in clinical chronic complications following sitagliptin monotherapy for 48 months in elderly patients with type 2 diabetes mellitus (T2DM).

Subjects and methods: We enrolled 76 drug-naïve patients (40 women and 36 men; mean age: 71.3±11.7 years) with T2DM who received 25-100 mg of sitagliptin therapy from an outpatient clinic. The observational period for each patient was >48 months, beginning at the time sitagliptin therapy was initiated. The following were measured or performed at the beginning of each year: body mass index; serum total cholesterol, low-density lipoprotein, high-density lipoprotein; triglyceride levels; creatinine (Cr) levels; urine albumin and urine Cr; nonmydriatic fundusgraphy; and semiquantified neuropathy. The fasting plasma glucose and glycated hemoglobin (HbA1c) was measured every 3-6 months.

Results: The change in HbA1c was significantly reduced after 6 months of therapy (7.1%±0.8% to 6.3%±0.2%). No changes in fasting plasma glucose, Cr, serum total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, body mass index, and microvascular complications were apparent. Using repeated measures to test the sequential changes in HbA1c from month 6 to month 48, the test of within-subjects effect was not significant (P=0.34).

Conclusion: Sitagliptin has a durable effect and stabilizes microvascular complication progression in elderly patients. This study can provide useful data for clinicians and health care professionals using sitagliptin monotherapy in the treatment of elderly patients with T2DM.

Show MeSH
Related in: MedlinePlus